日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Targeting tumor suppressor gene co-mutations in EGFR-mutant nonsmall cell lung cancer: How ACROSS2 sharpens the case for early intensification

针对EGFR突变型非小细胞肺癌中的抑癌基因共突变:ACROSS2如何强化早期强化治疗的必要性

Gunturu, Krishna S; Khan, Hina; de Lima Lopes, Gilberto Jr

Aumolertinib with carboplatin-pemetrexed versus aumolertinib for nonsmall cell lung cancer with EGFR and concomitant tumor suppressor genes (ACROSS2): An open-label, multicenter, randomized phase 3 study

奥莫替尼联合卡铂-培美曲塞对比奥莫替尼单药治疗EGFR和伴随肿瘤抑制基因的非小细胞肺癌(ACROSS2):一项开放标签、多中心、随机3期研究

Duan, Jian-Chun; Zhong, Jia; Sun, Bo-Yang; Zhao, Wen-Hua; Wu, Lin; Fei, Kai-Lun; Chu, Qian; Guo, Qi-Sen; Song, Qi-Bin; Yu, Yan; Zhu, Da-Xing; Liu, Xin-Yan; Zhao, Jun; Zhan, Zhi-Xiang; Li, Shi; Nie, Lei; Lin, Jie; Peng, Xiao-Dong; Zhong, Dian-Sheng; Zhou, Jin; Li, Li-Hua; Chen, Yun-Fang; Hu, Chen; Mok, Tony; Wang, Zhi-Jie; Wang, Jie

Innovative approaches for lung cancer screening and interception

肺癌筛查和拦截的创新方法

Zhang, Jianjun; Park, Matthew D; Pandya, Tej; Shum, Elaine; Wu, Jia; Heeke, Simon; Salehi-Rad, Ramin; Marron, Thomas U; Wei, Zhubo; Li, Hui; Blum, Torsten G; Heymach, John V; Dubinett, Steven M; Yang, Pan-Chyr; Swanton, Charles; Merad, Miriam

The evolving landscape of leptomeningeal metastases from NSCLC: an international, contemporary, multicenter cohort study

非小细胞肺癌软脑膜转移的演变格局:一项国际性、当代、多中心队列研究

Zheng, M M; Xia, Y; Pan, K; Sun, F; Tan, A C; Dong, X R; Tu, H Y; Tang, L B; Li, Y S; Yin, K; Borgeaud, M; Singhal, S; Zhu, E; Zhang, J; Nilsson, M; Wu, J; Gibbons, D L; Wakelee, H; Neal, J W; Lee, J; Vaporciyan, A A; Ringsurongkawong, W; Tran, H T; Zhang, R Z; Zhang, T; Zhou, Q; Zhong, W Z; Li, W; Zhang, Y C; Riess, J W; Addeo, A; Heymach, J V; Myall, N; Tan, D; Wu, Y L; Le, X

MTAP Loss Is Frequent in Oncogene-Driven NSCLC and May Confer Sensitivity to Combined PRMT5 Inhibitors and Targeted Therapies

MTAP缺失在癌基因驱动的非小细胞肺癌中很常见,并可能使肿瘤对PRMT5抑制剂和靶向治疗联合治疗敏感。

Aldea, M; Lenahan, S; Locquet, M-A; Liao, L; Gasparro, M; Gokhale, P C; Ghigna, M-R; Ionescu, D N; Odintsov, I; Ngo, K; Wang, X; Aziz, S; Pecci, F; Garbo, E; Ivanova, E; Nakazawa, S; Kulesza, J; Tsai, J A; Zullo, L; Lee, J; Zielinska, M; Simon, S; Han, D; Marinello, A; Li, G; Rossato de Almeida, G; Huang, J; Paoloni, F; Gariazzo, E; Santo, V; Remon, J; Marks, J A; LoPiccolo, J; Florez, N; Nishino, M; Ricciuti, B; Luo, J; Barbie, D A; Planchard, D; Rotow, J K; Barlesi, F; Graf, R P; Feng, W W; Besse, B; Paweletz, C; Sholl, L; Shaw, A T; Jänne, P A

Correction: Circulating tumor DNA refines consolidation immunotherapy for limited-stage small cell lung cancer patients

更正:循环肿瘤DNA可优化局限期小细胞肺癌患者的巩固免疫疗法

Yang, Yin; Wu, Yuqi; Zhao, Jingjing; Zhang, Tao; Fei, Kailun; Zhao, Xiaotian; Deng, Lei; Zhang, Zhihui; Jiang, Ying; Wang, Jianyang; Liu, Wenyang; Wang, Xin; Wang, Song; Bao, Hua; Wu, Xue; Zhu, Minyi; Ou, Qiuxiang; Tang, Wei; Wang, Luhua; Wang, Zhijie; Bi, Nan

First-line Aumolertinib (EGFR tyrosine kinase inhibitor) plus apatinib (VEGFR inhibitor) versus aumolertinib in EGFR-mutant non-small cell lung cancer patients: a randomized, multicenter, phase II trial

一线治疗EGFR突变型非小细胞肺癌患者,比较奥莫替尼(EGFR酪氨酸激酶抑制剂)联合阿帕替尼(VEGFR抑制剂)与奥莫替尼单药治疗的疗效:一项随机、多中心、II期临床试验

Zhang, Fan; Zheng, Zhendong; Zhang, Hongmei; Yan, Xiaolong; Liu, Zhefeng; Yang, Fan; Wen, Juyi; Gan, Xin; Wu, Lin; Cang, Shundong; Wang, Hongmei; Zhao, Jun; Peng, Liang; Li, Xiaosong; Fan, Zaiwen; Shen, Ge; Zhou, Qiong; Zou, Jinjing; Xu, Yu; Zhang, Lei; Zhao, Mingfang; Cai, Shangli; Hu, Yi

Perioperative penpulimab-based combination therapy in patients with resectable non-small cell lung cancer (ALTER-L043): an open-label, multicenter, randomized, phase II trial

围手术期以 Penpulimab 为基础的联合疗法治疗可切除非小细胞肺癌患者(ALTER-L043):一项开放标签、多中心、随机、II 期试验

Wang, Meng; Liu, Weiran; Guo, Hongbo; Long, Hao; Yu, Bentong; Zhao, Guofang; Wu, Jun; Yue, Dongsheng; Zhao, Xiaoliang; Li, Chenguang; Zhang, Lianmin; Wang, Shengguang; Zhang, Qiang; Zhang, Zhenfa; Wang, Changli

BMX inhibition overcomes small cell lung cancer chemoresistance by stabilizing E2F1 via ERK1/2-Cyclin D1/CDK4/6 axis.

BMX抑制剂通过ERK1/2-Cyclin D1/CDK4/6轴稳定E2F1,从而克服小细胞肺癌的化疗耐药性。

Wu Ting, Qi Shuang, Shi Chenliang, Wu Chao, Liu Qingwang, Hu Chen, Hu Jie, Wang Aoli, Liu Jing, Qi Ziping, Wang Wenchao, Liu Qingsong

GPR54 regulates non-small cell lung cancer development via dopa decarboxylase.

GPR54 通过多巴脱羧酶调控非小细胞肺癌的发展。

Hwang Hyun-Ha, Lee Seo Yeon, Lee Chanhee, Lee Jeong Yoon, Ko Seong-Gyu, Cho Sung-Gook